Printer Friendly

XOMA REPORTS 1992 FIRST QUARTER FINANCIAL RESULTS

 XOMA REPORTS 1992 FIRST QUARTER FINANCIAL RESULTS
 BERKELEY, Calif., April 24 /PRNewswire/ -- XOMA Corp.


(NASDAQ/NMS: XOMA) today announced its financial results for the 1992 first quarter.
 For the first quarter ended March 31, 1992, XOMA had revenues of $1.9 million and a net loss of $7.7 million ($0.36 per share). In the comparable 1991 period, XOMA had revenues of $5.1 million and a net loss of $6.6 million ($0.44 per share). The decline in revenues in the 1992 first quarter was due primarily to lower research and development fees from and product sales to Pfizer Inc., the company's marketing partner for its E5(R) anti-endotoxin monoclonal antibody product.
 At March 31, 1992, XOMA had total assets of $142.9 million including cash and short-term investments of $112.5 million, long-term debt of $1.4 million, and stockholders' equity of $127.2 million.
 XOMA is a leading biotechnology company in the development of pharmaceutical products based on monoclonal antibody and recombinant DNA technologies.
 XOMA CORP.
 Balance Sheet Data
 (In thousands) March 31, Dec. 31,
 1992 1991
 Current assets $126,907 $139,495
 Total assets 142,917 154,289
 Long-term debt 1,391 1,503
 Stockholders' equity 127,188 134,456
 Statement of Operations Three Months Ended
 (In thousands except per share data) Mar. 31,
 1992 1991
 Total revenues $1,946 $5,126
 Total operating costs and expenses 11,523 12,095
 Other income (expense) 1,885 345
 Net loss (7,692) (6,624)
 Net loss per share (0.36) (0.44)
 Weighted average common
 shares outstanding 21,430 14,895
 Shares outstanding at March 31, 1992: 21,440,439
 -0- 4/24/92
 /CONTACT: Carol D. DeGuzman of XOMA Corp., 510-644-1170/
 (XOMA) CO: XOMA Corp. ST: California IN: MTC SU: ERN


DG-RM -- SF003 -- 2508 04/24/92 13:27 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 24, 1992
Words:306
Previous Article:NICHOLAS DEBENEDICTIS ELECTED PRESIDENT AND CEO OF PHILADELPHIA SUBURBAN
Next Article:FIRST SOUTH SAVINGS, COLUMBIA, S.C., PLACED IN RECEIVERSHIP; DEPOSITS INSURED


Related Articles
XOMA ANNOUNCES YEAR-END FINANCIAL RESULTS
XOMA REPORTS 1992 SECOND QUARTER FINANCIAL RESULTS
XOMA ANNOUNCES NEW STRATEGIC FOCUS AND RESTRUCTURING
XOMA REPORTS 1992 THIRD QUARTER FINANCIAL RESULTS
XOMA ANNOUNCES YEAR-END FINANCIAL RESULTS
XOMA ANNOUNCES HUMAN CLINICAL TRIALS OF rBPI-23
XOMA REPORTS 1993 FIRST QUARTER FINANCIAL RESULTS
XOMA REPORTS SECOND QUARTER FINANCIAL RESULTS
XOMA REPORTS THIRD QUARTER FINANCIAL RESULTS
XOMA REPORTS FOURTH QUARTER, YEAR-END FINANCIAL RESULTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters